Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics

• US 20120294840A1
• Filed: 05/11/2012
• Published: 11/22/2012
• Est. Priority Date: 05/13/2011
• Status: Active Grant

• Current Assignee: Trustees of Boston College (Boston College), Glycosyn LLC
• Original Assignee: Glycosyn LLC Trustees of Boston College
• Inventors: Newburg, David S., McCoy, John M., Merighi, Massimo, Heidtman, Matthew Ian, Yu, Zhuoteng
• Granted Patent: US 9,567,361 B2
• Time in Patent Office: Days
• US Class Current: 424/93.44
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23L 33/21 Addition of substantially indigestible substances, e.g. dietary fibres
• CPC Class Codes: A23L 33/28 Substances of animal origin, e.g. gelatin or collagen
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 3/06 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics.

Claims

1. A method for stimulating the growth of a probiotic bacteria in a gastrointestinal tract of a mammalian subject, comprising administering to said subject a composition comprising a purified 2′

-FL, 3-FL, or LDFT.

2. A prebiotic composition comprising a purified human milk oligosaccharide in an amount effective to stimulate the growth of bacteria, wherein said oligosaccharide comprises purified 2′

-fucosyllactose (2′

-FL), purified 3-fucosyllactose (3-FL), or purified lactodifucotetraose (LDFT).

3. The prebiotic composition of claim 2, wherein said oligosaccharide comprises purified 2′

-FL and purified 3-FL.

4. The prebiotic composition of claim 2, wherein said oligosaccharide comprises purified 2′

-FL, purified 3-FL, and purified LDFT.

5. The prebiotic composition of claim 2, wherein said bacteria are commensal bacteria endogenous to the intestine of a mammalian subject.

6. The prebiotic composition of claim 2, wherein said bacteria are exogenously administered to a mammalian subject.

7. The prebiotic composition of claim 2, wherein said bacteria comprise bacteria of the genera Bifidobacterium, Lactobacillus, or Streptococcus.

8. The prebiotic composition of claim 2, wherein said bacteria are selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bacteroides vulgatus, Lactococcus lactis, and Streptococcus thermophilus.

9. The prebiotic composition of claim 2, wherein said composition comprises between 0.01 g 2′

-FL and 1 g 2′

-FL per gram of composition.

10. The prebiotic composition of claim 2, wherein said 2′

-FL comprises 90% to 99% by weight of said composition.

11. The prebiotic composition of claim 2, wherein said composition is in the form of a tablet, a capsule, a powder, or an infant formula.

12. The prebiotic composition of claim 2, wherein said composition is provided in dry milk, in mashed rice, in a banana, in a porridge, or in a gruel.

13. The prebiotic composition of claim 2, wherein said composition further comprises probiotic bacteria.

14. The prebiotic composition of claim 2, wherein said composition further comprises fructo-oligosaccharides (FOS) or galacto-oligosaccharides (GOS).

15. A method of stimulating the growth of bacteria in the gastrointestinal tract of a subject comprising administering to the gastrointestinal tract a composition comprising an effective amount of a purified human milk oligosaccharide, wherein said oligosaccharide comprises purified 2′

-fucosyllactose (2′

-FL), purified 3-fucosyllactose (3-FL), or purified lactodifucotetraose (LDFT).

16. The method of claim 15, wherein said 2′

-FL, said 3-FL, or said LDFT is 95-99% pure.

17. The method of claim 15, wherein the local pH in said gastrointestinal tract is decreased following administration of said composition.

18. The method of claim 15, wherein the local lactate or lactic acid concentration in said gastrointestinal tract is increased following administration of said composition.

19. The method of claim 15, wherein the growth of pathogenic bacteria in said gastrointestinal tract is inhibited following administration of said composition.

20. The method of claim 15, wherein said probiotic bacteria is selected from the group consisting of Bacteroides vulgates, Lactococcus lactis, Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, and Streptococcus thermophilus.

21. The method of claim 15, wherein said composition comprises between 0.01 g 2′

-FL and 1 g 2′

-FL per gram of composition.

22. The method of claim 15, wherein said composition further comprises probiotic bacteria selected from the group consisting of Bifidobacterium bifidum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bacteroides vulgatus, Lactococcus lactis, and Streptococcus thermophilus.

23. The method of claim 15, wherein said composition further comprises fructo-oligosaccharides (FOS) or galacto-oligosaccharides (GOS).

24. The method of claim 19, wherein said pathogenic bacteria is selected from the group consisting of Clostridium histolyticum, Clostridium difficile, Clostridium perfringens, Enterobacter aerogenes, Listeria monocytogenes, Staphylococcus aureus, Salmonella enterica, Yersinia enterocolitica, enterotoxigenic E. coli, and enteropathogenic E. coli.